ClinicalTrials.gg
CompletedNCT00888355Updated Jul 9, 2009Results posted

MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension

A Phase 3 interventional study of losartan potassium and Comparator: placebo in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2009-07-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
428
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.

Enrollment
7th of 65
428 · median 100
Started
1992
the only one that year
Phase 3
17 of 65
1 open now
Registered
20th of 65
by date
Lead sponsor
6 of 65
Merck Sharp & Dohme LLC

Among the 65 studies testing losartan in Hypertension, this one is the 7th largest by enrollment, is the only one that started in 1992, is one of 17 in phase 3, and was the 20th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing losartan in Hypertension, or all of them as a file.
02

Study summary

The study had a 4 week single blind placebo period followed by 12 weeks of double blind treatment. Patients were randomized to one of four treatment arms to evaluate the antihypertensive efficacy of Losartan.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has been diagnosed with mild to moderate hypertension
  • Patient has no treatment or active medical problem, other than hypertension that might affect the patients blood pressure

Exclusion criteria

Exclusion Criteria:

  • Pregnant of lactating female patients
  • Secondary hypertension or history of malignant hypertension
  • Sitting systolic blood pressure > 210 mmHg
  • History of stroke
  • History of myocardial infarction with in the past year
  • Current of prior history of heart failure
  • Known to losartan
  • Obesity
  • Patients known to be positive or known to be positive for
  • Absence of one kidney
  • Patient is abusing or previously abused alcohol or drugs with in past two years
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
428 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo

    Drug: Comparator: placebo

  • Experimental
    2

    Losartan 50 q.a.m.

    Drug: losartan potassium

  • Experimental
    3

    Losartan 25 b.i.d.

    Drug: losartan potassium

  • Experimental
    4

    Losartan 25 q.a.m.

    Drug: losartan potassium

Interventions

  • losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks

    Also known as: MK0954

  • DrugComparator: placebo

    placebo to losartan tablet q.a.m. , for 12 weeks

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12

    Mean change from baseline in trough (24 hours after the last morning dose and 12 hours after the last PM dose) SiDBP at Week 12

    Time frame: At baseline, and at 12 weeks (24 hours after last morning dose and 12 hours after last PM dose)

Secondary outcomes

  1. Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) as Week 12

    Mean change from baseline in trough (24 hours after the last morning dose and 12 hours after the last PM dose) SiSBP at Week 12

    Time frame: At baseline, and at 12 weeks (24 hours after last morning dose and 12 hours after last PM dose)

  2. Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12

    Mean change from baseline in peak (6 hours after the last morning dose) SiDBP at Week 12

    Time frame: At baseline and at 12 weeks (6 hours after last morning dose)

  3. Categories of Antihypertensive Response in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12

    Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg or increased were in Category III.

    Time frame: 24 hours after last morning dose and 12 hours after last PM dose at 12 weeks

Other outcomes

  1. Number of Patients With Clinical Adverse Experiences (CAEs)

    An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product

    Time frame: 12 weeks

  2. Number of Patients With Serious CAEs

    Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose

    Time frame: 12 weeks

  3. Number of Patients With Drug-related CAEs

    Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs during the 12-week treatment period

    Time frame: 12 weeks

  4. Number of Patients Discontinued Due to CAEs

    Patients discontinued due to CAEs during the 12-week treatment period

    Time frame: 12 weeks

  5. Number of Patients Who Died

    Patients who died during the 12-week treatment period

    Time frame: 12 weeks

  6. Number of Patients With Laboratory Adverse Experiences (LAEs)

    A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product

    Time frame: 12 weeks

  7. Number of Patients With Serious LAEs

    Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose

    Time frame: 12 weeks

  8. Number of Patients With Drug-related LAEs

    Patients with drug-related LAEs during the 12-week treatment period

    Time frame: 12 weeks

  9. Number of Patients Discontinued Due to LAEs

    Patients discontinued due to LAEs during the 12-week treatment period

    Time frame: 12 weeks

07

Results

Posted Jun 24, 2009
Limitations and caveats
Note that deaths are not entered under "drop reasons" in the participant flow panel because the patients who died are already counted as dropped due to adverse event.

Participant flow

Patients were recruited at 37 sites in the United States. Prime Therapy Period: May, 1992 to January1993

Participant flow — Overall Study
MilestonePlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
Started108108106106
Completed86999496
Not completed2291210
Withdrew: Adverse event10033
Withdrew: Lack of efficacy9252
Withdrew: Lost to follow-up0220
Withdrew: Protocol violation3212
Withdrew: Withdrawal by subject0313

Outcome measures

PrimaryMean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12

Mean change from baseline in trough (24 hours after the last morning dose and 12 hours after the last PM dose) SiDBP at Week 12

Time frame:
At baseline, and at 12 weeks (24 hours after last morning dose and 12 hours after last PM dose)
Reported as:
Mean · mm Hg
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
mm HgPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12-2.0 ± 8.4-5.8 ± 6.7-6.3 ± 7.4-8.0 ± 7.9
SecondaryMean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) as Week 12

Mean change from baseline in trough (24 hours after the last morning dose and 12 hours after the last PM dose) SiSBP at Week 12

Time frame:
At baseline, and at 12 weeks (24 hours after last morning dose and 12 hours after last PM dose)
Reported as:
Mean · mm Hg
Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) as Week 12
mm HgPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) as Week 12-0.2 ± 15.1-7.2 ± 13.9-7.6 ± 12.6-8.8 ± 13.0
SecondaryMean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12

Mean change from baseline in peak (6 hours after the last morning dose) SiDBP at Week 12

Time frame:
At baseline and at 12 weeks (6 hours after last morning dose)
Reported as:
Mean · mm Hg
Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12
mm HgPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12-3.0 ± 9.7-7.7 ± 8.5-8.7 ± 8.1-9.9 ± 9.5
SecondaryCategories of Antihypertensive Response in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12

Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg or increased were in Category III.

Time frame:
24 hours after last morning dose and 12 hours after last PM dose at 12 weeks
Reported as:
Number · Participants
Categories of Antihypertensive Response in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
ParticipantsPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
Category I12232633
Category II10141415
Category III80686153
Other pre-specifiedNumber of Patients With Clinical Adverse Experiences (CAEs)

An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Patients With Clinical Adverse Experiences (CAEs)
ParticipantsPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
With CAEs63595960
Without CAEs45494746
Other pre-specifiedNumber of Patients With Serious CAEs

Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Patients With Serious CAEs
ParticipantsPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
With Serious CAEs4113
Without Serious CAEs104107105103
Other pre-specifiedNumber of Patients With Drug-related CAEs

Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs during the 12-week treatment period

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Patients With Drug-related CAEs
ParticipantsPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
With drug-related CAEs20122116
Without drug-related CAEs88968590
Other pre-specifiedNumber of Patients Discontinued Due to CAEs

Patients discontinued due to CAEs during the 12-week treatment period

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Patients Discontinued Due to CAEs
ParticipantsPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
Discontinued due to CAEs10013
Not discontinued due to CAEs98108105103
Other pre-specifiedNumber of Patients Who Died

Patients who died during the 12-week treatment period

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Patients Who Died
ParticipantsPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
Who Died2001
Alive106108106105
Other pre-specifiedNumber of Patients With Laboratory Adverse Experiences (LAEs)

A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Patients With Laboratory Adverse Experiences (LAEs)
ParticipantsPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
With LAEs7774
Without LAEs979896100
Other pre-specifiedNumber of Patients With Serious LAEs

Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Patients With Serious LAEs
ParticipantsPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
With serious LAEs0000
Without serious LAEs104105103104
Other pre-specifiedNumber of Patients With Drug-related LAEs

Patients with drug-related LAEs during the 12-week treatment period

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Patients With Drug-related LAEs
ParticipantsPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
With drug-related LAEs4540
Without drug-related LAEs10010099104
Other pre-specifiedNumber of Patients Discontinued Due to LAEs

Patients discontinued due to LAEs during the 12-week treatment period

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Patients Discontinued Due to LAEs
ParticipantsPlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)
Discontinued due to LAEs0020
Not discontinued due to LAEs104105101104

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)Total
Mean54.6 ± 10.653.0 ± 10.754.0 ± 10.152.4 ± 10.153.5 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)Total
Female38413636151
Male70677070277
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)Total
Caucasian84798289334
Oriental12227
Latin American01001
Black2122171070
Hispanic245415
Vietnamese00011
Sitting Diastolic Blood Pressure (SiDBP)
Sitting Diastolic Blood Pressure (SiDBP)(mm Hg)PlaceboLosartan 25 mg q.d.Losartan 50 mg q.d.Losartan 25 mg (b.i.d.)Total
Mean101.5 ± 5.1101.8 ± 5.5102.4 ± 6.4102.0 ± 5.3101.9 ± 5.6
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 1992, a primary completion of Jan 1993 and a completion of Feb 1993. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 16 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2009
First posted
Apr 27, 2009
Start
May 1992
Primary completionActual
Jan 1993
CompletionActual
Feb 1993
Results first posted
Jun 24, 2009
Last update
Jul 9, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00888355
First posted
Apr 27, 2009
Start date
May 1992
Primary completion
Jan 1993
Completion
Feb 1993
Results posted
Jun 24, 2009
Last update
Jul 9, 2009

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion